Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode pages of FDA jargon and clinical-trial tables in CeriBell’s disclosures? Medical-device filings are notoriously dense, and CeriBell’s focus on AI-driven EEG technology only adds layers of regulatory nuance. Whether you’re hunting for cybersecurity risks tied to VA deployments or details on subscription revenue, finding answers quickly can feel impossible.
Our platform fixes that. Stock Titan’s AI reads every CeriBell annual report 10-K simplified, flags key FDA 510(k) milestones in each CeriBell quarterly earnings report 10-Q filing, and delivers plain-English takeaways you can act on. Need to monitor CeriBell insider trading Form 4 transactions? We stream CeriBell Form 4 insider transactions real-time, alerting you the moment an executive buys or sells. Material news breaks? A fresh 8-K appears and we publish CeriBell 8-K material events explained within minutes.
The result is clarity. Use our AI to compare R&D spend trends, track device-unit placements, or probe management incentives inside the next CeriBell proxy statement executive compensation. Dive into a concise CeriBell earnings report filing analysis or ask a natural question such as “understanding CeriBell SEC documents with AI” and get answers fast. From risk-factor red-flags to CeriBell executive stock transactions Form 4, every insight lives here—updated in real time and explained simply. No more endless scrolling through EDGAR; confident decisions start now.
CeriBell (CBLL) reported Q3 2025 results with total revenue of $22.589 million, up from $17.195 million a year ago, driven by product revenue of $17.020 million and subscription revenue of $5.569 million. Gross profit was $19.942 million.
Operating expenses rose to $34.589 million, leading to a net loss of $13.465 million (basic and diluted loss per share $0.37). For the nine months, revenue reached $64.279 million with a net loss of $39.885 million.
Liquidity remained strong with $168.5 million in cash, cash equivalents, and marketable securities as of September 30, 2025 (
Ceribell, Inc. (CBLL) furnished an update on its latest performance, announcing that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company stated that the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act, nor incorporated by reference under the Securities Act unless specifically referenced.
CeriBell, Inc. filed a universal shelf registration to offer up to $300,000,000 of securities — including common stock, preferred stock, debt securities, warrants, and units — to be sold from time to time in one or more offerings. A prospectus supplement will set the specific amounts, prices, and terms for each takedown and may update the base disclosures.
The company may sell through underwriters, dealers, agents, directly to purchasers, or a combination of these methods. Use of proceeds will be described in the applicable supplement. CeriBell’s common stock trades on the Nasdaq Global Select Market under “CBLL”; the last reported price was $11.34 per share on November 3, 2025.
Ceribell, Inc. (CBLL) insider activity on
Mr. Woo exercised 1,472 options at a
Ceribell, Inc. (CBLL) notice reports proposed and completed insider sales of common stock. An insider planned to sell 11,112 shares through Fidelity Brokerage Services LLC with an aggregate market value of $139,314.51, and the filing lists 36,663,968 shares outstanding. The securities to be sold were acquired via stock options granted on 07/07/2021 (1,472 shares) and 02/16/2023 (9,640 shares), with payment noted as cash. The form also discloses a completed sale by Raymond Woo of 11,112 shares on 09/04/2025 for gross proceeds of $134,609.74. The filer certifies no undisclosed material adverse information and includes standard Rule 144 and Rule 10b5-1 notices.
Ceribell director Erica J. Rogers filed an initial Form 3 reporting her relationship to Ceribell, Inc. (CBLL) with an event date of 09/17/2025. The filing states that no securities are beneficially owned by the reporting person. The form was signed by an attorney-in-fact, Louisa Daniels, on 09/19/2025, and includes Exhibit 24 (Power of Attorney).
Ceribell, Inc. (CBLL) director Erica J. Rogers was granted 25,216 restricted stock units (RSUs) on 09/17/2025. The RSUs are reported at a $0 transaction price, and following the grant she is shown as beneficially owning 25,216 shares on a direct basis. The Form 4 was signed on behalf of Ms. Rogers by attorney-in-fact Louisa Daniels on 09/19/2025. The filing identifies Ms. Rogers as a director and indicates this is a single-person Form 4 filing for the issuer Ceribell, Inc., ticker CBLL. No derivative securities or other transactions are reported in this filing.
Ceribell, Inc. (CBLL) insider amendment corrects earlier Form 4 by reporting option exercises the CEO and director executed on April 22 and April 23, 2025. The reporting person, President and CEO Xingjuan Chao, exercised options at $2.24 per share: 300 options on 04/22/2025 and 15,628 options on 04/23/2025. Those exercises increased reported beneficial ownership to 752,451 shares after 04/22 and to 768,079 shares after 04/23. The filing states the transactions were effected under a Rule 10b5-1 trading plan and that the omitted exercises caused understatement in the original filing’s ownership totals. The amendment clarifies that the stock options are fully vested and exercisable.
FAQ
What is the current stock price of CeriBell (CBLL)?
What is the market cap of CeriBell (CBLL)?
